Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

120 Risultati di ricerca.

A Phase II Study of AZD4877 (a Novel Anti-mitotic DRKS00004052 - Eligibility Bladder Cancer NCT00661609

- 27/09/21 - 1 modulo, 2 itemgroups, 8 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see http://clinicaltrials.gov/ct2/show/study/NCT00661609

Pharmacokinetic Study of Doxorubicin in Children With Cancer DRKS00003787 NCT01095926 - 1st Sampling period

- 27/09/21 - 2 moduli, 20 itemgroups, 113 elementi, 1 linguaggio

Itemgroups: Physical Examination, Determination of cardiac function (before sampling period), Clinical chemistry, Haematology, Agents that are known to interact with doxorubicin according to SmPCs administered?, Antiemetic agents administered?, Cardioprotective agents administered?, Systemic antimycotic agents, Other agents administered?, Actual protocol block, Start of actual protocol block, Chemotherapy in actual protocol block administered ?, Previous anthracycline treatment, Doxorubicin treatment in 1st sampling period, Haematological toxicity of actual protocol block, Transfusions, Determination of cardiac function (end of sampling period), Adverse events, Start of next protocol block, Footer module

Official Title: Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity. https://clinicaltrials.gov/ct2/show/NCT01095926 NCT01095926

Registration

6 itemgroups 25 elementi

Eligibility DRKS00009656 NCT00069745 Prostate Cancer - Eligibility

- 20/09/21 - 1 modulo, 3 itemgroups, 34 elementi, 2 lingue

Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Inclusion Criteria: - Stage D2 metastatic prostate cancer - Progression after one prior chemotherapy - ECOG Performance status equal / less than 2 - Life expectancy > 3 months - Surgical or medical castration - Adequate bone marrow, hepatic and renal functions - Informed consent Exclusion Criteria: - More than one prior chemotherapy - Prior platinum containing compounds - Prior malignancy - Prior significant RT/radionuclide therapy - Major GI surgery or GI disease affecting absorption - Disease with contraindication to steroids - Brain metastases

EGF100262 lapatinib in Squamous Cell Carcinoma Female Demography - EGF100262 Squamous Cell CaEGF100262 lapatinib in Squamous Cell Carcinoma Female Demographyrcinoma Female Demography

- 20/09/21 - 1 modulo, 1 ItemGroup, 4 elementi, 1 linguaggio

ItemGroup: Demography for Females

A Phase I, Open Label, Multicentre, Dose-escalation Study of Oral GW572016 in Combination with Radiation Therapy and Cisplatin in Patients with Stage III-IV Squamous Cell Carcinoma of the Head and Neck.

Eligibility NCT00915252 Acute Myeloid Leukemia - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 24 elementi, 2 lingue

Itemgroups: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00915252

Eligibility NCT00844064 Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 33 elementi, 2 lingue

Itemgroups: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00844064

Eligibility DRKS00000733 NCT00867672 Acute Myeloid Leukemia - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 19 elementi, 2 lingue

Itemgroups: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00867672

Eligibility NCT00858364 Non-Small Cell Lung Cancer - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 33 elementi, 2 lingue

Itemgroups: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00858364

CALGB: 90104 SPECIMEN SUBMISSION FORM NCT00014534

- 20/09/21 - 1 modulo, 3 itemgroups, 23 elementi, 1 linguaggio

Itemgroups: Header, Patient demographics, SPECIMEN SUBMISSION

CALGB: 90104 SPECIMEN SUBMISSION FORM NCT00014534 Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E5F4A97F-274E-398C-E034-0003BA3F9857

Eligibility DRKS00003686 NCT00761280 Anaplastic Astrocytoma - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 47 elementi, 2 lingue

Itemgroups: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00761280

Eligibility DRKS00003778 NCT00749723 Recurrent Brain Tumors - Eligibility

- 20/09/21 - 1 modulo, 1 ItemGroup, 25 elementi, 2 lingue

ItemGroup: Inclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00749723

Eligibility Metastatic Colorectal Carcinoma FOLFOX6 or FOLFIRI Combined With Sorafenib NCT00889343

- 20/09/21 - 1 modulo, 2 itemgroups, 39 elementi, 2 lingue

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma NCT00889343 ODM derived from http://clinicaltrials.gov/show/NCT00889343

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.